ALPPS as a Technique to Minimize Small For Size Syndrome after Major Hepatectomy for Neuroendocrine Tumour Metastases. Abstract #2158

Introduction: Liver resection has emerged as an effective treatment for secondary liver neuroendocrine tumours. “Associated liver partition and portal vein ligation for staged hepatectomy” (ALPPS) allows resection of liver tumours in 2 steps.
Aim(s): We present our experience in ALPPS procedure as a method which can minimize small for size syndrome, and provide an oncological benefit to borderline resectable neuroendocrine tumours within acceptable safety profile.
Materials and methods: 4 patients underwent ALPPS procedure for clearance of the metastatic liver disease. Segments I, IV-VIII were resected for each patient. 2 of the patients had bi-lobar disease. Clearance to the future liver remnant (FLR) was achieved with non-anatomical liver resection in 1 case and with irreversible electroporation to the other as the lesion was adjacent to the left hepatic vein during the 1st stage of the ALPPS procedure. 2 patients underwent ALPPS as a salvage procedure after failed portal vein embolisation and ligation respectively.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Michail Pizanias

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#2274 Liver Resection for Neuroendocrine Tumors Liver Metastases in Transplantable Patients within the Milan Criteria
Introduction: Liver transplantation (LT) has been prosed as a curative treatment for metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) but there is a lack of consensus on its real benefit when compared with hepatectomy.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Andrea Ruzzenente
#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Johann Dréanic
#1481 Neuroendocrine Liver Metastasis: A Novel Nomogram to Predict Patient’s Prognosis After Liver Resection
Introduction: Despite surgery remains the only potentially curative option for patients with neuroendocrine liver metastases (NELMs), the factors determining the prognosis of patients following hepatectomy are poorly understood.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Fabio Bagante